I'm LongbridgeAI, I can summarize articles.OPKO Health disclosed a 29.6% stake in Cocrystal Pharma, acquired via a $5 million purchase of over 5.47 million shares on July 31, 2026. This investment deepens existing ties, including board roles for OPKO executives Phillip Frost and Steven D. Rubin. The transaction was made for investment purposes under a Securities Purchase Agreement, with voting rights governed by a Stockholders Rights Agreement linked to the RFS Pharma merger.
OPKO Health, Inc. disclosed a 29.6% stake in Cocrystal Pharma, Inc. common stock. The filing, dated Aug. 07, 2026, follows OPKO’s July 31 purchase of 5,474,053 shares for $5 million. The move deepens long-standing ties that already include board roles for Phillip Frost and Steven D. Rubin.
Investor Intent
OPKO bought the shares for investment purposes under a July 31, 2026 Securities Purchase Agreement. The parties remain linked by a Stockholders Rights Agreement tied to the earlier RFS Pharma merger, under which the investors "granted an irrevocable proxy" on voting to designated individuals and received "a right of first refusal" to join future equity financings until Cocrystal raises $70 million.
Frost and Rubin continue to serve on Cocrystal’s board, positioning the group to influence strategy through governance channels. OPKO also states it will keep reviewing the investment and could adjust its holdings over time.
Investor's Background
OPKO Health, Inc. is a diversified healthcare company incorporated in Delaware and led by Chairman and CEO Phillip Frost, M.D. The company invests across diagnostics and pharmaceuticals and often takes strategic equity positions in partners. OPKO has a track record of long-term, deal-driven growth in life sciences, combining internal development with targeted investments.
Original SEC Filing: Cocrystal Pharma, Inc. [ COCP ] - SCHEDULE 13D - Aug. 07, 2026